University of Texas MD Anderson Cancer Center
Houston, Texas, United States
Pavlos Msaouel is a physician-scientist dedicated to translational research for renal cell carcinomas, with a particular emphasis on rare variants such as renal medullary carcinoma (RMC). His laboratory focuses on elucidating the pathogenesis and identifying targetable vulnerabilities for renal cell carcinoma subtypes. His research identified distinct genomic and immune hallmarks of RMC and led to the development of testable models of RMC pathogenesis resulting in the identification of high-intensity exercise as a potential risk factor for RMC. The latter was achieved via the introduction of structural causal modeling to the oncology field. In collaboration with Juhee Lee and Peter Thall, Dr. Msaouel developed the covariate-specific utility function framework for modeling patient heterogeneity. Dr. Msaouel serves as the principal investigator of several completed and ongoing investigator-initiated clinical trials. He designed and led the phase I-II trial that identified the optimal dose of sitravatinib in combination with nivolumab in clear cell renal cell carcinoma based on efficacy, toxicity, and patient-reported quality of life.
Disclosure information not submitted.